Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 25Neoplasm Metastasis 6Ovarian Neoplasms 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Advanced Breast Cancer 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Uterine Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Melanoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genital Neoplasms, Female 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 16Bevacizumab 12Carboplatin 10Nivolumab 8Pemetrexed 7Temozolomide 6Standard of Care 6Exercise 6Cetuximab 6durvalumab 5atezolizumab 5Prednisone 5Cyclophosphamide 5abemaciclib 4Paclitaxel 4Doxorubicin 4Dexamethasone 4Cisplatin 4Blood Specimen Collection 4temsirolimus 3enzalutamide 3dostarlimab 3daratumumab 3cabozantinib 3Sunitinib 3Rituximab 3Oxaliplatin 3Metformin 3Leucovorin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Fulvestrant × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Atavistik Bio, Inc

Phase 1 Active not recruiting
134 enrolled
BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡